Insider Transactions in Q1 2023 at C4 Therapeutics, Inc. (CCCC)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 15
2023
|
Andrew Hirsch President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
81,600
+42.9%
|
-
|
|
Feb 13
2023
|
Lauren White Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+45.54%
|
-
|
|
Feb 13
2023
|
Kelly Schick Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+44.35%
|
-
|
|
Feb 13
2023
|
Scott N Boyle Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+44.27%
|
-
|
|
Feb 13
2023
|
Jolie Siegel Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+44.35%
|
-
|
|
Feb 13
2023
|
Stewart Fisher Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+20.24%
|
-
|
|
Feb 08
2023
|
Utpal Koppikar Director |
BUY
Open market or private purchase
|
Direct |
5,667
+50.0%
|
$28,335
$5.6 P/Share
|
|
Jan 30
2023
|
Jolie Siegel Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-20.33%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Jolie Siegel Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+36.95%
|
-
|
|
Jan 30
2023
|
Kelly Schick Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-20.33%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Kelly Schick Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+36.95%
|
-
|
|
Jan 30
2023
|
Andrew Hirsch President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,319
-13.79%
|
$30,233
$7.78 P/Share
|
|
Jan 30
2023
|
Andrew Hirsch President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+28.52%
|
-
|
|
Jan 30
2023
|
Scott N Boyle Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,222
-19.1%
|
$8,554
$7.78 P/Share
|
|
Jan 30
2023
|
Scott N Boyle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+36.95%
|
-
|
|
Jan 30
2023
|
Lauren White Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-20.33%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Lauren White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+36.95%
|
-
|
|
Jan 30
2023
|
Adam Crystal Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-6.08%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+14.91%
|
-
|
|
Jan 30
2023
|
Stewart Fisher Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,301
-1.67%
|
$9,107
$7.78 P/Share
|
|
Jan 30
2023
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+4.6%
|
-
|
|
Jan 06
2023
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
712
+0.37%
|
$2,136
$3.55 P/Share
|
|
Jan 03
2023
|
Glenn Dubin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,725
+24.78%
|
$10,350
$6.38 P/Share
|
|
Jan 03
2023
|
Donna Roy Grogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,763
+40.58%
|
$10,578
$6.38 P/Share
|
|
Jan 03
2023
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,568
+1.63%
|
$9,408
$6.38 P/Share
|